Study Summary
This study will provide long-term follow-up for patients who have received treatment with JCAR015 in a previous clinical trial. In this study, patients will be followed for up to 15 years after their last dose of JCAR015 for evaluation of delayed adverse events, presence of persisting JCAR015 vector sequences, and survival.
Want to learn more about this trial?
Request More InfoInterventions
JCAR015GENETIC
No study drug is administered in this study. Patients who received JCAR015 in a previous trial will be evaluated in this trial for long-term safety and efficacy.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Northwestern University | Chicago | Illinois | United States |
| Johns Hopkins Sidney Kimmel Comprehensive Cancer Center | Baltimore | Maryland | United States |
| Washington University School of Medicine | St Louis | Missouri | United States |
| Memorial Sloan Kettering Cancer Center | New York | New York | United States |